William Blair & Company
ARCT icon

William Blair & Company’s Arcturus Therapeutics ARCT Stock Holding History

William Blair & Company’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,735
Closed -$284K – 1807
2024
Q4 		$284K Sell
16,735
-1,095
-6% -$20.6K ﹤0.01% 1307
2024
Q3 		$414K Hold
17,830
– – ﹤0.01% 1176
2024
Q2 		$434K Sell
17,830
-305
-2% -$9.25K ﹤0.01% 1137
2024
Q1 		$612K Sell
18,135
-570
-3% -$20.2K ﹤0.01% 1036
2023
Q4 		$590K Hold
18,705
– – ﹤0.01% 1030
2023
Q3 		$478K Buy
+18,705
New +$576K ﹤0.01% 1068

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

William Blair & Company's ARCT Position: Q1 2025 in Review

William Blair & Company sold out of Arcturus Therapeutics (ARCT) in Q1 2025, closing a stake of 16,735 shares — an estimated $284K sold.

William Blair & Company first reported a position in ARCT in Q3 2023 and held it in 6 quarters. The position peaked at $612K in Q1 2024. 144 funds tracked by Wall St. Rank hold ARCT as of Q1 2025.

  • William Blair & Company reported no remaining Arcturus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • William Blair & Company sold 16,735 Arcturus Therapeutics shares in Q1 2025, an estimated $284K.
  • William Blair & Company first reported a position in Arcturus Therapeutics in Q3 2023 and held it in 6 quarters.
  • William Blair & Company's Arcturus Therapeutics position peaked at $612K in Q1 2024.
  • 144 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2025.

Based on William Blair & Company's 13F filing for Q1 2025, filed 9 May 2025.